Madrigal Pharmaceuticals, Inc. (MDGL)
NASDAQ · Healthcare
Madrigal Pharmaceuticals, Inc. EBITDA 2012–2025
Madrigal Pharmaceuticals, Inc. annual/quarterly ebitda history and growth rate from 2012 to 2026. EBITDA stands for Earnings Before Interest, Taxes, Depreciation and Amortization. It is widely used as a measure of core operational profitability.
- Madrigal Pharmaceuticals, Inc. ebitda for the quarter ending March 31, 2026 was -92.3 M, a 16.98% increase year-over-year.
- Madrigal Pharmaceuticals, Inc. ebitda for the twelve months ending March 31, 2026 was -401.4 M, a 141.32% increase year-over-year.
- Madrigal Pharmaceuticals, Inc. annual ebitda for 2025 was -298.6 M, a 39.89% decrease from 2024.
- Madrigal Pharmaceuticals, Inc. annual ebitda for 2024 was -496.8 M, a 30.74% increase from 2023.
- Madrigal Pharmaceuticals, Inc. annual ebitda for 2023 was -380.0 M, a 29.64% increase from 2022.
- Madrigal Pharmaceuticals, Inc. annual ebitda for 2022 was -293.1 M.
EBITDA
TRAILING 12 MONTHS · $B
QUARTERLY · $B
YEAR-OVER-YEAR GROWTH · %
Madrigal Pharmaceuticals, Inc. EBITDA — FAQ
Madrigal Pharmaceuticals, Inc. (MDGL) ebitda over the last 10 years — annual and quarterly figures with year-over-year growth and charts.
Where can I see MDGL's ebitda history?
The chart and table above show Madrigal Pharmaceuticals, Inc.'s ebitda by year and by quarter, including the growth rate.